Category: BioUtah News

Halia Therapeutics Dosed its First Patient in Phase 2a Clinical Trial of HT-6184, a First-in-Class NLRP3-Inhibitor, for the Treatment of Lower-Risk Myelodysplastic Syndromes

Posted on by admin

LEHI, Utah /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the dosing of the first patient in Phase 2a clinical trial evaluating its lead candidate, HT-6184, for the treatment of lower-risk myelodysplastic syndromes (LR-MDS). HT-6184 is a selective and orally bioavailable first-in-class […]

Read More

RxCell Announces $4.6M Investment from DMR Global Venture and Regenosis, Plans for Second Raise of $15M for IND Testing in Q4 2023

Posted on by admin

SINGAPORE–(BUSINESS WIRE)–RxCell, a pioneering biotech company focusing on cellular therapeutics for age-related diseases, today proudly announces a $4,600,000 investment commitment from DMR Global Venture LLC and Regenosis. Building on the strength of collaboration with National University of Singapore, this fresh investment accentuates RxCell’s resolute drive to revolutionize age-related disease treatment. “We’re thrilled to align with […]

Read More

Culmination Bio Raises $10M From Amgen Ventures and Merck Global Health Innovation Fund to Bring Longitudinal Health Data to Biopharma

Posted on by admin

Culmination Bio has over 40 years of biospecimen data and counting, paired with clinical data from patient EHRs, making recruitment for pharmaceutical research almost instantaneous. St. George, Utah — (November 30, 2023) — Culmination Bio, a company building the largest disease-agnostic patient data intelligence platform, today announced a $10 million investment from Merck Global Health […]

Read More

SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK – ENROLLMENT TO STOP DUE TO SUCCESS

Posted on by admin

SALT LAKE CITY, Dec. 6, 2023 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal […]

Read More